Literature DB >> 24397940

Intravesical lipiodol injection technique for image-guided radiation therapy for bladder cancer.

Adam S Baumgarten1, Justin B Emtage1, Richard B Wilder2, Matthew C Biagioli2, Shilpa Gupta1, Philippe E Spiess3.   

Abstract

INTRODUCTION: To describe the technique of injecting Lipiodol in the submucosa of the urinary bladder wall as a novel modality to improve localization of muscle-invasive bladder tumors before image-guided radiation therapy. TECHNICAL CONSIDERATIONS: Eight patients underwent submucosal Lipiodol injections at transurethral bladder tumor reresection. A rigid cystoscope with a working port was used to inject Lipiodol into bladder submucosa circumferentially around the tumor bed (2-3 mm from margin of resection). Approximately 20-30 injections were used to demarcate the tumor bed for external beam radiation therapy, which was used as part of a bladder-sparing approach. All patients were diagnosed with clinically localized, high-grade, muscle-invasive carcinoma and were deemed nonsurgical candidates or were unwilling to undergo radical cystectomy. Five of the 8 patients received radiation at our institution. Lipiodol injections (95%) were visible on treatment planning computed tomographic scans and kilovoltage portal images throughout the 7-week course of image-guided radiation therapy. In 2 of 5 patients, the tumor bed based on Lipiodol extended outside a planning target volume that would have been treated with radiation therapy based on cystoscopy reports and computed tomographic scans without Lipiodol. There were no adverse events or treatment-related toxicities secondary to Lipiodol injection.
CONCLUSION: Intravesical Lipiodol injection is an easy-to-perform technique that is safe and effective. Lipiodol serves as a fiducial marker that improves tumor bed localization for radiation therapy, thereby reducing the likelihood of missing the tumor.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24397940     DOI: 10.1016/j.urology.2013.09.058

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

1.  Lipiodol injections for optimization of target volume delineation in a patient with a second tumor of the oropharynx: A case report.

Authors:  Marlen Haderlein; Ricarda Merten; Andrea Stojanovic; Stefan Speer; Claudia Scherl; Rainer Fietkau; Oliver J Ott
Journal:  Strahlenther Onkol       Date:  2015-06-04       Impact factor: 3.621

Review 2.  Trimodality therapy in bladder cancer: who, what, and when?

Authors:  Christopher Premo; Andrea B Apolo; Piyush K Agarwal; Deborah E Citrin
Journal:  Urol Clin North Am       Date:  2015-05       Impact factor: 2.241

3.  Potential for BioXmark liquid fiducial marker to improve identification of superficial component of canine oral tumors for computer-based radiation therapy planning.

Authors:  Benoit Clerc-Renaud; Mary-Keara Boss; Lynn R Griffin; Susan M LaRue; Del Leary
Journal:  Can Vet J       Date:  2019-10       Impact factor: 1.008

4.  A multi-institutional study of bladder-preserving therapy for stage II-IV bladder cancer: A Korean Radiation Oncology Group Study (KROG 14-16).

Authors:  Sang Jun Byun; Won Park; Kwan Ho Cho; Jaeho Cho; Ah Ram Chang; Ki Mun Kang; Jin Ho Kim; Jin Hee Kim
Journal:  PLoS One       Date:  2019-01-17       Impact factor: 3.240

Review 5.  MR-Guided Adaptive Radiotherapy for Bladder Cancer.

Authors:  Adham Hijab; Boris Tocco; Ian Hanson; Hanneke Meijer; Christina Junker Nyborg; Anders Smedegaard Bertelsen; Robert Jan Smeenk; Gillian Smith; Jeff Michalski; Brian C Baumann; Shaista Hafeez
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

6.  Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes.

Authors:  Muhammad Shahbaz; Asif Ammar; Yuliang Wang; Zeeshan Farhaj; Liang Qiao; Jun Niu
Journal:  Int Braz J Urol       Date:  2021 Jan-Feb       Impact factor: 1.541

7.  A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy.

Authors:  Matthew D Greer; Stephanie K Schaub; Stephen R Bowen; Jay J Liao; Kenneth Russell; Jonathan J Chen; Emily S Weg; Juergen Meyer; Tristan Alving; George R Schade; John L Gore; Sarah P Psutka; Robert B Montgomery; Michael Schweizer; Evan Y Yu; Petros Grivas; Jonathan L Wright; Jing Zeng
Journal:  Adv Radiat Oncol       Date:  2021-11-21

8.  BioXmark® liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial.

Authors:  Mischa de Ridder; Lara C Gerbrandy; Theo M de Reijke; Karel A Hinnen; Maarten C C M Hulshof
Journal:  Br J Radiol       Date:  2020-06-01       Impact factor: 3.039

9.  Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis.

Authors:  Yeon Joo Kim; Sang Jun Byun; Hanjong Ahn; Choung-Soo Kim; Beom-Sik Hong; Sangjun Yoo; Jae-Lyun Lee; Young Seok Kim
Journal:  Oncotarget       Date:  2017-03-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.